SCHEMBL23537463

SCHEMBL23537463

O=C1CCCc2[nH]c(=O)c3c(c21)COCC3

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
ALOX15 P16050 1/20 0.42
ALDH1A1 P00352 4/20 0.37
MAPT P10636 2/20 0.37
PTK2 Q05397 1/20 0.36
TSHR P16473 3/20 0.34
DYRK1A Q13627 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
WNT3A P56704 10/20 0.33
TNKS2 Q9H2K2 10/20 0.33
LMNA P02545 2/20 0.32
RAB9A P51151 2/20 0.32
TNKS O95271 1/20 0.32
NPC1 O15118 1/20 0.32
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23537289 0.94 SMN1; SMN2 (0.38) SMN1; SMN2ALOX15ALDH1A1MAPTPTK2
SCHEMBL23537321 0.85 ALOX15 (0.35) SMN1; SMN2ALOX15ALDH1A1MAPTWNT3A
SCHEMBL9802990 0.81 SMN1; SMN2 (0.57) SMN1; SMN2ALOX15ALDH1A1MAPTPTK2
SCHEMBL9803418 0.79 SMN1; SMN2 (0.61) SMN1; SMN2ALOX15ALDH1A1MAPTPTK2
SCHEMBL23537742 0.79 WNT3A (0.34) SMN1; SMN2ALOX15ALDH1A1MAPTWNT3A
SCHEMBL23537564 0.68 ALOX15 (0.36) SMN1; SMN2ALOX15WNT3ATNKS2
SCHEMBL5462185 0.67 SMN1; SMN2 (0.48) SMN1; SMN2ALOX15ALDH1A1MAPTPTK2
SCHEMBL23537555 0.66 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1
SCHEMBL23537489 0.65 ALOX15 (0.33) SMN1; SMN2ALOX15WNT3ATNKS2
SCHEMBL18236841 0.65 ALDH1A1 (0.53) SMN1; SMN2ALOX15ALDH1A1MAPTWNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230108906-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-04-06 US disclosed
EP-4076648-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-10-26 EP disclosed
CN-115087486-A Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof 爱彼特生物制药公司 2022-09-20 CN disclosed
WO-2021127356-A1 Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same ARBUTUS BIOPHARMA, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108906-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME DDC, CDA, HMBS SMN1; SMN2 4530/4885ALOX15 4219/4885ALDH1A1 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.